185 related articles for article (PubMed ID: 31423334)
1. Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
Eniu A; Cherny NI; Bertram M; Thongprasert S; Douillard JY; Bricalli G; Vyas M; Trapani D
ESMO Open; 2019; 4(4):e000483. PubMed ID: 31423334
[TBL] [Abstract][Full Text] [Related]
2. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
Cherny NI; Sullivan R; Torode J; Saar M; Eniu A
Ann Oncol; 2017 Nov; 28(11):2633-2647. PubMed ID: 28950323
[TBL] [Abstract][Full Text] [Related]
3. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.
Cherny N; Sullivan R; Torode J; Saar M; Eniu A
Ann Oncol; 2016 Aug; 27(8):1423-43. PubMed ID: 27457309
[TBL] [Abstract][Full Text] [Related]
4. Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories.
Ithimakin S; Parinyanitikul N; Kim SB; Yap YS; Tsang J; Soong IS; Ozaki Y; Ohno S; Ono M; Chan JJ; Cheng HCS; Dejthevaporn T;
J Breast Cancer; 2022 Jun; 25(3):207-217. PubMed ID: 35657002
[TBL] [Abstract][Full Text] [Related]
5. Access to essential anticancer medicines for children and adolescents in Europe.
Vassal G; Kozhaeva O; Griskjane S; Arnold F; Nysom K; Basset L; Kameric L; Kienesberger A; Kamal S; Cherny N; Bricalli G; Latino N; Kearns P
Ann Oncol; 2021 Apr; 32(4):560-568. PubMed ID: 33388384
[TBL] [Abstract][Full Text] [Related]
6. Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally: the Kazakh experience.
Latino NJ; Galotti M; Cherny NI; de Vries EGE; Douillard JY; Kaidarova D; Ilbawi A
ESMO Open; 2022 Feb; 7(1):100362. PubMed ID: 35246325
[TBL] [Abstract][Full Text] [Related]
7. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
[TBL] [Abstract][Full Text] [Related]
8. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.
Zarkavelis G; Amylidi AL; Verbaanderd C; Cherny NI; Metaxas Y; de Vries EGE; Zygoura P; Amaral T; Jordan K; Strijbos M; Dafni U; Latino N; Galotti M; Lordick F; Giuliani R; Pignatti F; Pentheroudakis G
ESMO Open; 2023 Feb; 8(1):100604. PubMed ID: 36870739
[TBL] [Abstract][Full Text] [Related]
9. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
10. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
11. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe.
Bayle A; Bonastre J; Chaltiel D; Latino N; Rouleau E; Peters S; Galotti M; Bricalli G; Besse B; Giuliani R
Ann Oncol; 2023 Oct; 34(10):934-945. PubMed ID: 37406812
[TBL] [Abstract][Full Text] [Related]
12. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit.
Hofmarcher T; Szilagyiova P; Gustafsson A; Dolezal T; Rutkowski P; Baxter C; Karamousouli E
ESMO Open; 2023 Aug; 8(4):101593. PubMed ID: 37413761
[TBL] [Abstract][Full Text] [Related]
13. Generic medicines policies in the Asia Pacific region: ways forward.
Nguyen TA; Hassali MAA; McLachlan A
WHO South East Asia J Public Health; 2013; 2(1):72-74. PubMed ID: 28612828
[TBL] [Abstract][Full Text] [Related]
14. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey.
Trapani D; Lengyel CG; Habeeb BS; Altuna SC; Petrillo A; El Bairi K; Hussain S; Mazher SA; Elfaham EM; Curigliano G; Khan SZ
J Cancer Policy; 2021 Jun; 28():100285. PubMed ID: 35559914
[TBL] [Abstract][Full Text] [Related]
15. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
16. The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology.
Cherny NI; Cleary J; Scholten W; Radbruch L; Torode J
Ann Oncol; 2013 Dec; 24 Suppl 11():xi7-13. PubMed ID: 24436961
[TBL] [Abstract][Full Text] [Related]
17. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative.
Cherny NI; Baselga J; de Conno F; Radbruch L
Ann Oncol; 2010 Mar; 21(3):615-626. PubMed ID: 20176694
[TBL] [Abstract][Full Text] [Related]
18. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
19. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
Janzic U; Knez L; Janzic A; Cufer T
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
[No Abstract] [Full Text] [Related]
20. A Survey of Home Enteral Nutrition Practices and Reimbursement in the Asia Pacific Region.
Wong A; Banks MD; Bauer JD
Nutrients; 2018 Feb; 10(2):. PubMed ID: 29443950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
